Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells - Wikidata - wikimedia - TriplyDB

Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells

Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells

http://www.wikidata.org/entity/Q34876201

about

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing.Suppression of COUP-TFII by proinflammatory cytokines contributes to the pathogenesis of endometriosis.Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes HDAC3 acts as a negative regulator of angiogenesis.Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2 The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.Onco-Golgi: Is Fragmentation a Gate to Cancer Progression?Quantitative PPARγ expression affects the balance between tolerance and immunity.Dual-specificity phosphatases 2: surprising positive effect at the molecular level and a potential biomarker of diseases.Profile of gene expression of TLR-signaling pathways in colorectal cancer tissues.Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer.Human Microtumors Generated in 3D: Novel Tools for Integrated In Situ Studies of Cancer Immunotherapies.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Coordination of AUF1 and miR-148a destabilizes DNA methyltransferase 1 mRNA under hypoxia in endometriosis.MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.Downregulation of PHLPP expression contributes to hypoxia-induced resistance to chemotherapy in colon cancer cells.HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis.The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation.Functional Analysis of Dual-Specificity Protein Phosphatases in Angiogenesis.Hypoxia Promotes Gastric Cancer Malignancy Partly through the HIF-1α Dependent Transcriptional Activation of the Long Non-coding RNA GAPLINC.Crosstalk and signaling switches in mitogen-activated protein kinase cascades Hypoxia-inhibited dual-specificity phosphatase-2 expression in endometriotic cells regulates cyclooxygenase-2 expression.Targeting hypoxia-mediated YAP1 nuclear translocation ameliorates pathogenesis of endometriosis without compromising maternal fertility.Hypoxia-inhibited DUSP2 expression promotes IL-6/STAT3 signaling in endometriosis.MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.Inhibition of dual specificity phosphatase-2 by hypoxia promotes interleukin-8-mediated angiogenesis in endometriosis.Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer.The impact of phosphatases on proliferative and survival signaling in cancer.Multicellular tumor spheroid formation in duplex microcapsules for analysis of chemosensitivity.Hypoxia-regulated gene network in drug resistance and cancer progression.

P2860

Q28391884-C3B4CDD3-1BDD-496B-9E9F-FF06F2A65223 Q30557271-481C7D80-E8A5-4968-AB82-FA1B2973E5AC Q33570074-946BBCC9-18CC-43E9-A9F3-909F5E89CA90 Q34084057-74A85214-4351-49C8-BAD0-AD34009C4998 Q34180080-D3E8AE5F-994C-4505-B794-4A6A2219C950 Q35172962-A6591A8B-EB1D-4D21-98C4-1157D164144C Q35273305-A1ED44F8-5A87-41FA-9B07-CABE39A61B7A Q35911372-2814AE6A-FA60-4B93-853D-88B63D2F530C Q36582865-A3E848D9-5EB0-474F-B036-09F78494DB50 Q36776494-FD4128F4-3328-4D2B-82C7-FBF77A696D31 Q36933990-3E761E98-584C-46E9-A04F-F28179BEB036 Q38063356-19357ED0-6956-4927-A62F-0ACC06AF7D0A Q38370227-3B959D93-A4FE-482C-A1F9-F1627A229BC8 Q38724150-D5521B70-A218-4E32-BF0B-A701BC2AA850 Q38782039-7F941373-51D7-4F62-B2B3-4F18477C2E17 Q38812867-81D96C18-75A7-4F50-9EC1-126BA6F822A7 Q38830552-821D3FB5-ACB2-4C32-A58E-0DACD8132E1F Q39037653-0155EC30-31DF-4B1F-A04F-F758D8A65868 Q39092675-EDF45BB3-01D8-4CA0-B454-2E4F5ABB22B9 Q39324644-B7CF6667-7DE2-4078-B76D-02BC73BC1840 Q40417033-E222684E-49E7-4498-B33F-599D0FC93F6C Q40579475-A458FCE0-A99E-471D-A60E-DA3117C7CC22 Q41188373-A4E528AC-96EE-46AB-A2BF-EAD3DC2CD533 Q41771446-C7AC585A-ED85-44DA-84A9-1982B748DD25 Q45910538-E4DB3915-9AF1-48B4-AF6B-5E7E80FD585F Q47864626-91FD77C2-7286-47A1-A658-744FDE2D7C3E Q48235750-207B53C9-F4A1-4BDB-914E-2A87DB498464 Q50897000-EC358664-5B9E-40D3-9BBD-FAE438B42BCF Q51506836-4ADA6F4F-4E66-4C05-8E4E-E14C590A26CF Q52655173-0B3D7679-EAD9-4C76-A6EB-C427F1ABCB66 Q54112403-EE090D8B-38AA-41A1-AD60-60CE6756B57C Q54334094-0A0E6EF3-2AAF-4314-AD9F-ADA8F22D4899 Q54354000-EC4C47E1-D35F-4A85-93B5-463DDBC34A60

P2860

Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells

http://www.wikidata.org/entity/Q34876201

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Suppression of dual-specificit ...... lignancy in human cancer cells

@ast

Suppression of dual-specificit ...... lignancy in human cancer cells

@en

Suppression of dual-specificit ...... lignancy in human cancer cells

@nl

type

label

Suppression of dual-specificit ...... lignancy in human cancer cells

@ast

Suppression of dual-specificit ...... lignancy in human cancer cells

@en

Suppression of dual-specificit ...... lignancy in human cancer cells

@nl

prefLabel

Suppression of dual-specificit ...... lignancy in human cancer cells

@ast

Suppression of dual-specificit ...... lignancy in human cancer cells

@en

Suppression of dual-specificit ...... lignancy in human cancer cells

@nl

P1433

Q34876201-196BE6B6-47EF-4B69-95B9-718AE9B72CC2

P1476

Q34876201-EF09D915-D2F0-4208-A4E7-F2D5864929FF

P2093

Q34876201-013162AC-8B6C-40A0-A646-44676A4E8F85

Q34876201-07DA98CD-3A5A-45B4-AA43-2F1709EDD42D

Q34876201-1D1C0135-B028-485D-B843-208E32E24CB9

Q34876201-2CD25F71-249E-475E-BEF0-DD92B2E59E1A

Q34876201-66F3F121-49B6-441E-8A7C-50208589E6EC

Q34876201-91D5474C-765D-492B-BF91-530226ED5413

Q34876201-98A615F0-FCC6-489E-90FF-F360FFAE57B9

Q34876201-F1F61B1D-A0DA-4578-833D-48F7AE605449

P2860

Q34876201-14CD62AF-97C7-4B18-A52D-F6A21DC90E50

Q34876201-18ACA20E-12BB-4F22-A401-ED886BC2521B

Q34876201-19B7E670-CD2A-4E41-A142-AC2905695892

Q34876201-1AD7818E-0B1D-441F-A34A-F09AA6C36F7D

Q34876201-2301D920-8897-4EED-ADF8-E482D37236C2

Q34876201-3068CA90-BEDA-4DF0-9620-149D7DECEC4D

Q34876201-331545FF-9CB6-4643-940D-F139D1D6C70B

Q34876201-37EB2BAA-8351-45EF-8743-CDBBA759C344

Q34876201-37FB6FD0-BC57-4D1C-94D6-7F4655B84F47

Q34876201-3CF8E131-7E60-4FA8-B025-D43873C29099

P304

Q34876201-3F86A54F-4BAD-4379-A95B-CC2C2AF7BEB8

P31

Q34876201-B533A9E4-613D-4E16-8758-EBCD9A6AB8AC

P356

Q34876201-9F863AD4-4AF8-4821-8331-57169FF499AC

P407

Q34876201-D3B82CDA-A9DC-464E-947A-D7248196F640

P433

Q34876201-3A1F2A0A-4B60-423E-99A0-E95DF789C321

P478

Q34876201-C0D89230-D3B3-4B21-814C-69F09234F36C

P577

Q34876201-A1C55F0E-0922-43EC-A99D-29C316440781

P5875

Q34876201-18A0072D-9870-4A2D-A5B9-4B9611FFD589

P698

Q34876201-00D56D8B-014F-45F3-9660-BDD4207E96CD

P921

Q34876201-83B8A0EA-B8F1-4E16-AF3C-5EBF2D05443D

P932

Q34876201-B5CDCA0E-9E03-46AB-93B8-101170A6F80E

P356

P1433

Journal of Clinical Investigation

P1476

Suppression of dual-specificit ...... lignancy in human cancer cells

@en

P2093

Chun-Wei Chien

http://www.w3.org/2001/XMLSchema#string

Jenq-Chang Lee

http://www.w3.org/2001/XMLSchema#string

Keng-Fu Hsu

http://www.w3.org/2001/XMLSchema#string

Shao-Chieh Lin

http://www.w3.org/2001/XMLSchema#string

Shaw-Jenq Tsai

http://www.w3.org/2001/XMLSchema#string

Shih-Chieh Lin

http://www.w3.org/2001/XMLSchema#string

Yen-Yu Lai

http://www.w3.org/2001/XMLSchema#string

Yi-Chun Yeh

http://www.w3.org/2001/XMLSchema#string

P2860

MAP kinase phosphatases

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

A conserved family of prolyl-4-hydroxylases that modify HIF

New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding

PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase

Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Exploiting tumour hypoxia in cancer treatment

Protein tyrosine phosphatases in the human genome

P304

1905-1916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI44362

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51048824

http://www.w3.org/2001/XMLSchema#string

P698

21490398

http://www.w3.org/2001/XMLSchema#string

P921

P932

3083779

http://www.w3.org/2001/XMLSchema#string